The General Clinical Research Center (GCRC) has long been recognized as one of the University's most mportant resources. A long history of outstanding research and a stable supportive environment encourages multidisciplinary teams of investigators to work together on the GCRC. Events of the past have further focused the University's attention on the vital role patient oriented research plays in the overall research enterprise. And the University's strategic plan for the future places clinical investigation, and the GCRC, even more prominently. This five year competitive renewal is submitted to continue the availability of facilities and resources to promote continued growthin clinical investigation of the highest quality at VCU. Eighty-nine protocols from 26 groups of investigators representing all five schools (Medicine, Dentistry, Nursing, Pharmacy and Allied Health) on the MCV campus of VCU are included in this application. Areas of nvestigation include obesity, exercise physiology, cardiovascular disease, periodontal disease, hypertension, diabetes mellitus, polycystic ovary syndrome, hepatitis C, non-alcoholic fatty liver disease, ?ehabilitation medicine, HIV/AIDS, breast cancer, hematologic malignancies, sickle cell anemia, substance abuse, transplant surgery, and alternative strategies for pain management.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-48
Application #
7749022
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Mccloskey, Donna J
Project Start
1997-01-20
Project End
2010-06-30
Budget Start
2009-12-01
Budget End
2010-06-30
Support Year
48
Fiscal Year
2010
Total Cost
$806,732
Indirect Cost
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42

Showing the most recent 10 out of 366 publications